USA-based Q BioMed (OTCMKTS: QBIO) has bought the worldwide rights to the US Food and Drug Administration-approved drug strontium chloride (SR89) with the promise to keep prices down.
Q BioMed did the deal with fellow US firm Bio-Nucleonics, which it expects to pay $850,000 in cash and an aggregate of 110,000 shares of common stock.
SR89 provides long-lasting relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. The drug is preferentially absorbed in bone metastases and has been proven to provide a long-term effect resulting in non-narcotic cancer pain relief and enhanced quality of life.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze